A Big Day Awaits Karnua Therapeutics

Trump supporters are in a cult, and Mitch McConnell is one of them, says Dan Rather

President Donald Trump’s followers are part of a “cult” — and that includes Senate Majority Leader Mitch McConnell, longtime news anchor Dan Rather said Sunday.

Speaking on CNN’s “Reliable Sources with Brian Stelter” on Sunday morning, Rather, the former CBS News anchor, said Trump’s support is “all about him.”

“These cults, cults generally don’t end well,” Rather said. “People will say it’s too much to say it’s a cult. I don’t think so. The further we go, it is always all about him. It’s not about a policy.”

When asked specifically if McConnell, the Kentucky Republican, was part of that cult, Rather said: “The short answer is yes.”

Speaking about the impeachment inquiry, and allegations that Trump tried to bribe a foreign government and intimidate witnesses, Rather said of Trump: “I’d say history is closing in on him, facts are closing in.”

Still, because of that cult-like following, “whether or not that’s enough to have a real trial in the Senate or not, I have my doubts,” he said.

Rather isn’t the only one saying Trump supporters are part of a cult. A report last week by Vanity Fair said outspoken anti-Trump Republican George Conway, whose wife is White House adviser Kellyanne Conway, “tells people she’s in a cult.”

Dan Rather Accuses Mitch McConnell Of Being Part Of Donald Trump ‘Cult’

Legendary newsman Dan Rather on Sunday accused Senate Majority Leader Mitch McConnell (R-Ky.) of being part of the troubling “cult” of President Donald Trump.

“Increasingly, President Trump’s support seems cultish,” Rather told Brian Stelter on CNN’s “Reliable Sources,” noting: “I’m not the only one making this observation.”

It’s “all about him, it’s not about the policy, it’s not about the standards of politics,” he explained.

“Cults generally don’t end well,” he said, echoing a tweet he posted Friday.  

Asked by Stelter if he considered McConnell part of the cult, Rather said: “The short answer is yes.”

Rather said the question lawmakers have to decide for impeachment is if Trump tried to “bribe” a foreign government with military aid to investigate a political rival, and if he tried to “intimidate witnesses.” He added: “I’d say history is closing in on him, facts are closing in” on Trump. But Rather said he doubts the Senate will hold a “real” impeachment trial. 

The cult concept appears to part a growing narrative about the president’s pull on the Republican Party and his supporters. Sources told Vanity Fair for an article last week that conservative attorney George Conway, husband of White House counselor Kellyanne Conway, has complained that his wife is part of the Trump “cult.”

Check out Rather’s comments in the video above.

Morgan Stanley Sees a Global Economic Recovery in Early 2020

In this article

Risks remain skewed to the downside, including the potential for more tariffs and late-cycle challenges in the U.S., including corporate credit risk and uncertainty around the elections.

If the Trump administration follows through on its threat to impose additional tariffs on Chinese goods in December, global growth will decelerate further in the final quarter of this year “and the recovery will be delayed until 3Q20,” the authors write.

Still, a mini-cycle recovery should kick in next year. Constant interruptions to the global cycle over the past decade have kept a lid on any overheating and helped avert a steep recession, according to Morgan Stanley’s economists.

“Hence, with this mini-cycle recovery – the third in the last decade – we believe that the late-cycle expansion can be extended,“ they wrote.

California at heightened risk of wildfires, blackouts this week

The National Weather Service issued high-level fire warnings for Southern California on Sunday, while PG&E Corp. warned of more power outages in Northern California where high winds and dry conditions also posed a fire risk.

PG&E PCG, +10.75% , California’s largest power company, said it might cut electricity starting Wednesday for roughly 180,000 homes and businesses around San Jose, Santa Rosa, and in the Sierra foothills. All have already experienced preventive blackouts intended to reduce the danger of winds damaging power lines and igniting fires.

The National Weather Service’s “Red Flag” warnings were in effect into Monday for areas including the mountains of Los Angeles County and the Santa Clarita and San Fernando valleys because of dry, hot weather.

“Any new fire ignitions will have the potential for rapid fire spread and extreme fire behavior, especially considering the very dry fuels in place,” the federal government weather agency said.

An expanded version of this report appears on WSJ.com.

Also popular on WSJ.com:

Mainland Chinese soldiers take to Hong Kong streets for first time during protests.

Colin Kaepernick, NFL exchange fire after league-organized workout goes awry.

A Big Day Awaits Karnua Therapeutics

Karuna Therapeutics (KRTX) is all set for the big day as the Company is scheduled to report results from its phase II clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia on Monday.

KarXT, the Company’s lead drug candidate, is an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues. The compound combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS.

The phase II trial of KarXT is a multi-site, double-blind, 182-patient study whose primary endpoint is the change from baseline in Positive and Negative Syndrome Score (PANSS) total scores for KarXT compared to placebo-treated patients.

The release of KarXT trial results on Monday (Nov.18, 2019) is the first clinical trial catalyst for Karuna since going public with its initial public offering on the Nasdaq Global Market on June 28, 2019.

The Company will also be exploring the potential of KarXT for the treatment of psychosis in Alzheimer’s disease and pain, and phase 1b clinical trials for the two indications are expected to commence by the end of 2019.

KRTX has thus far hit a low of $11.24 and a high of $29.00. The stock closed Friday’s trading at $17.68, up 1.67%.